Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.5 USD | -0.58% | +2.41% | -29.00% |
Sales 2024 * | 821M 1.13B | Sales 2025 * | 1.2B 1.65B | Capitalization | 5.16B 7.09B |
---|---|---|---|---|---|
Net income 2024 * | -129M -177M | Net income 2025 * | 105M 144M | EV / Sales 2024 * | 5.89 x |
Net cash position 2024 * | 322M 443M | Net cash position 2025 * | 717M 985M | EV / Sales 2025 * | 3.71 x |
P/E ratio 2024 * |
-44.1
x | P/E ratio 2025 * |
42.4
x | Employees | 704 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.68% |
Latest transcript on Apellis Pharmaceuticals, Inc.
1 day | -0.58% | ||
1 week | +2.41% | ||
Current month | +8.28% | ||
1 month | +1.21% | ||
3 months | -27.35% | ||
6 months | -31.19% | ||
Current year | -29.00% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 54 | 09-09-24 | |
Cedric Francois
FOU | Founder | 51 | 09-09-24 |
Timothy Sullivan
DFI | Director of Finance/CFO | 53 | 17-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alec Machiels
FOU | Founder | 51 | 09-09-24 |
Director/Board Member | 65 | 13-06-30 | |
Paul R. Fonteyne
BRD | Director/Board Member | 62 | 20-04-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.61% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - | |
0.19% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 42.5 | -0.58% | 1,001,460 |
24-06-11 | 42.75 | +2.52% | 612,969 |
24-06-10 | 41.7 | +3.29% | 897,286 |
24-06-07 | 40.37 | -1.66% | 508,744 |
24-06-06 | 41.05 | -1.08% | 1,061,817 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.00% | 5.16B | |
+0.46% | 91.38B | |
-2.37% | 38.68B | |
+72.12% | 27.84B | |
-12.31% | 16.05B | |
-4.54% | 13.48B | |
-10.83% | 11.73B | |
+180.20% | 10.74B | |
-48.60% | 10.39B | |
+2.10% | 8.94B |
- Stock Market
- Equities
- APLS Stock